Comparing different types of stem cells used in cardiovascular research.

 

Though located in the shadow of the well-respected University of California, San Francisco, The J. David Gladstone Institutes has built a sterling reputation of its own for scientific discovery and innovation. Composed of three independent, nonprofit research institutes, Gladstone has a remarkable ability to combine extraordinary scientific talent and advanced technology to illuminate important factors in the causes and potential strategies for curing some of the major diseases of our time.

 

                            Deena Dubal, MD, PhD, focuses on Alzheimer’s disease.

Its state-of-the-art laboratories at San Francisco’s Mission Bay biotechnology hub house embrace some of the leading scientific talent and technology, focusing on heart disease, Alzheimer’s and other neurological diseases, HIV/AIDS, and regenerative medicine.

Gladstone’s new president R. Sanders Williams, MD and president emeritus Robert Mahley, MD, PhD at San Francisco’s Mission Bay.

 

Among their many contributions to understanding disease processes, Gladstone scientists have elucidated the role of cholesterol in heart disease, identified the complex mechanisms that may cause Alzheimer’s disease, and found potential avenues to interfere with the ability of HIV to infect cells. Most recently, in one of the most important scientific advances of the decade, Shinya Yamanaka, past postdoctoral fellow and current Gladstone investigator, discovered a method for turning adult skin cells into embryonic-like, or induced pluripotent stem (iPS) cells.

 

Josh Arnold, stem cell core manager, reviews images of stem cells that have been coaxed into different types of cells.
 

With competition for scientists and funding from more widely known California neighbors, Gladstone has quietly grown its reputation as one of the best places to work in U.S. academia and as a top destination for training postdoctoral fellows.

 

                                 A neuron reprogrammed from a stem cell.

 

“We have the best of both worlds here,” said Gladstone president, R. Sanders Williams, MD. “The San Francisco Bay Area is an epicenter for scientific collaboration. We have access to the talent and innovation that exist within the universities and industry here, but we have the independence to enable us to pursue the high-risk, high-return research that can make a difference.”





Comments are closed.

 

 


hey